{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:13:57Z","timestamp":1793139237167,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.phrs.2018.11.014","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T05:54:49Z","timestamp":1543298089000},"page":"395-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":476,"special_numbering":"C","title":["Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.11.014_bib0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.11.014_bib0010","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/1097-0142(19830515)51:10<1787::AID-CNCR2820511004>3.0.CO;2-A","article-title":"The epidermal growth factor (EGF)","volume":"51","author":"Cohen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2018.11.014_bib0015","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0020","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0021-9258(19)68224-4","article-title":"A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles","volume":"257","author":"Cohen","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcell.2016.00088","article-title":"The under-appreciated promiscuity of the epidermal growth factor receptor family","volume":"4","author":"Kennedy","year":"2016","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0030","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.11.014_bib0035","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2004.05.018","article-title":"Protein tyrosine phosphatases in the human genome","volume":"117","author":"Alonso","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.11.014_bib0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0050","first-page":"7","article-title":"Cancer statistics","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2018.11.014_bib0055","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2018.11.014_bib0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.11.014_bib0065","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"Citri","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0070","first-page":"1","article-title":"The neuregulin-I\/ErbB signaling system in development and disease","volume":"190","author":"Britsch","year":"2007","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0075","doi-asserted-by":"crossref","first-page":"H543","DOI":"10.1152\/ajpheart.91436.2007","article-title":"Cardiac ErbB-1\/ErbB-2 mutant expression in young adult mice leads to cardiac dysfunction","volume":"295","author":"Rajagopalan","year":"2008","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/376337a0","article-title":"Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor","volume":"376","author":"Miettinen","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.11.014_bib0085","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/378390a0","article-title":"Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor","volume":"378","author":"Gassmann","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.11.014_bib0090","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/378394a0","article-title":"Requirement for neuregulin receptor erbB2 in neural and cardiac development","volume":"378","author":"Lee","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.11.014_bib0095","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/39593","article-title":"Severe neuropathies in mice with targeted mutations in the ErbB3 receptor","volume":"389","author":"Riethmacher","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.11.014_bib0100","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1080\/02841860903229124","article-title":"Cardiotoxicity induced by tyrosine kinase inhibitors","volume":"48","author":"Orphanos","year":"2009","journal-title":"Acta Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0105","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/309418a0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.11.014_bib0110","doi-asserted-by":"crossref","first-page":"26761","DOI":"10.1074\/jbc.272.42.26761","article-title":"A novel juxtamembrane domain isoform of HER4\/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester","volume":"272","author":"Elenius","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0115","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/0008-5472.CAN-10-1872","article-title":"Trastuzumab has preferential activity against breast cancers driven by ERBB2 homodimers","volume":"71","author":"Ghosh","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0120","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0125","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1128\/MCB.16.10.5276","article-title":"A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor\/neuregulin and epidermal growth factor","volume":"16","author":"Tzahar","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0130","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/emboj\/16.7.1647","article-title":"ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling","volume":"16","author":"Graus-Porta","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.11.014_bib0135","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/j.1460-2075.1996.tb00603.x","article-title":"Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions","volume":"15","author":"Pinkas-Kramarski","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.11.014_bib0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1677\/erc.0.0080075","article-title":"The Type 1 growth factor receptors and their ligands considered as a complex system","volume":"8","author":"Gullick","year":"2001","journal-title":"Endocr. Rel. Cancer"},{"key":"10.1016\/j.phrs.2018.11.014_bib0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrm1548","article-title":"ADAMs: key components in EGFR signalling and development","volume":"6","author":"Blobel","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biochi.2007.08.008","article-title":"Emerging roles of ADAM and ADAMTS metalloproteinases in cancer","volume":"90","author":"Rocks","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.phrs.2018.11.014_bib0155","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.11.014_bib0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0165","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1096\/fasebj.9.13.7557015","article-title":"How do protein kinases discriminate between serine\/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase","volume":"9","author":"Taylor","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2018.11.014_bib0170","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0006-291X(92)90812-Y","article-title":"A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor","volume":"186","author":"Gotoh","year":"1992","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.11.014_bib0175","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond., B, Biol. Sci."},{"key":"10.1016\/j.phrs.2018.11.014_bib0180","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0185","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0190","doi-asserted-by":"crossref","first-page":"18756","DOI":"10.1074\/jbc.M110.206193","article-title":"Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein","volume":"286","author":"Aertgeerts","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0200","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0205","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0215","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0230","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0240","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2018.11.014_bib0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0260","series-title":"Reference Module in Life Sciences","first-page":"1","article-title":"Src family tyrosine kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2018.11.014_bib0265","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0275","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1073\/pnas.94.8.3565","article-title":"Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates","volume":"94","author":"Shah","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0280","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2018.11.014_bib0285","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2018.11.014_bib0290","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2018.11.014_bib0295","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0300","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0305","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.11.014_bib0310","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0315","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2018.11.014_bib0320","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United states food and drug administration drug approval summary: gefitinib (ZD1839; iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0325","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.phrs.2018.11.014_bib0330","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2018.11.014_bib0335","doi-asserted-by":"crossref","first-page":"E3595","DOI":"10.1073\/pnas.1220050110","article-title":"Mechanism for activation of mutated epidermal growth factor receptors in lung cancer","volume":"110","author":"Red Brewer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0340","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.cell.2006.05.013","article-title":"An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor","volume":"125","author":"Zhang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.11.014_bib0345","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMct0807960","article-title":"Treatment of non-small-cell lung cancer with erlotinib or gefitinib","volume":"364","author":"Cataldo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0350","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1582-4934.2009.00991.x","article-title":"Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis","volume":"14","author":"Paz-Ares","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0355","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0360","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2018.11.014_bib0365","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.11.014_bib0370","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.11.014_bib0375","doi-asserted-by":"crossref","first-page":"64600","DOI":"10.18632\/oncotarget.19925","article-title":"Clinical strategies for acquired epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small-cell lung cancer patients","volume":"8","author":"Dong","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2018.11.014_bib0380","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-319-91442-8_18","article-title":"Osimertinib","volume":"211","author":"Malapelle","year":"2018","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0385","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0390","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.2012.43.0652","article-title":"Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?","volume":"31","author":"Mok","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0395","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1021\/acs.jmedchem.6b00883","article-title":"Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family","volume":"59","author":"Smaill","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0400","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.2147\/DDDT.S52787","article-title":"Dacomitinib in lung cancer: a \"lost generation\" EGFR tyrosine-kinase inhibitor from a bygone era?","volume":"9","author":"Ou","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.phrs.2018.11.014_bib0405","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1200\/JCO.2018.78.7994","article-title":"Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations","volume":"36","author":"Mok","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0410","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jtho.2018.01.009","article-title":"EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib","volume":"13","author":"Kobayashi","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0415","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jtho.2018.03.025","article-title":"First-in-human phase I study of AC0010, a mutant-selective EGFR inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance","volume":"13","author":"Ma","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0420","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.phrs.2017.01.003","article-title":"Targeting EGFR T790M mutation in NSCLC: from biology to evaluation and treatment","volume":"117","author":"Passaro","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0425","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1021\/jm020241c","volume":"46","author":"Wissner","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0430","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1200\/JCO.2005.01.8960","article-title":"Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors","volume":"24","author":"Erlichman","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0435","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/med.21488","article-title":"Targeting EGFRL858R\/T790M and EGFRL858R\/T790M\/C797S resistance mutations in NSCLC: current developments in medicinal chemistry","volume":"38","author":"Lu","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2018.11.014_bib0440","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19840201)53:3+<630::AID-CNCR2820531308>3.0.CO;2-3","article-title":"Steroid-hormone receptors in breast cancer","volume":"53","author":"Wittliff","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2018.11.014_bib0445","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1517\/14656566.8.4.485","article-title":"Docetaxel\/anthracycline combinations for breast cancer treatment","volume":"8","author":"von Minckwitz","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2018.11.014_bib0450","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2018.11.014_bib0455","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0460","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1185\/03007995.2012.707643","article-title":"Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC)","volume":"28","author":"Riemsma","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.phrs.2018.11.014_bib0465","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fonc.2018.00089","article-title":"Current therapies for human epidermal growth factor receptor 2-positive metastatic breast cancer patients","volume":"8","author":"Larionov","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0470","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fonc.2018.00156","article-title":"Efficacy of anti-HER2 agents in combination with adjuvant or neoadjuvant chemotherapy for early and locally advanced HER2-positive breast cancer patients: a network meta-analysis","volume":"8","author":"Debiasi","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0475","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/jm040159c","article-title":"Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity","volume":"48","author":"Tsou","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0480","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.18632\/oncotarget.1148","article-title":"Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer","volume":"4","author":"Canonici","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2018.11.014_bib0485","first-page":"2183","article-title":"Novel treatment strategies for patients with HER2-positive breast cancer who do not benefit from current targeted therapy drugs","volume":"16","author":"Jiang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0490","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","article-title":"U.S. Food and Drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer","volume":"24","author":"Singh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0495","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s40265-017-0811-4","article-title":"Neratinib: first global approval","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2018.11.014_bib0500","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0505","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0510","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2018.11.014_bib0515","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2018.11.014_bib0520","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"58","key":"10.1016\/j.phrs.2018.11.014_bib0525","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1021\/jm501603h","article-title":"Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors","volume":"8","author":"Vijayan","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0530","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0535","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/acschembio.5b01018","article-title":"Conformation-selective analogues of dasatinib reveal insight into kinase inhibitor binding and selectivity","volume":"11","author":"Kwarcinski","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0540","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.chembiol.2018.05.002","article-title":"Redefining the protein kinase conformational space with machine learning","volume":"25","author":"Ung","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0545","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0550","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0555","first-page":"197","article-title":"Kinase-centric computational drug development","volume":"50","author":"Kooistra","year":"2017","journal-title":"Ann. Rep. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0560","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0565","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0570","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/med.21409","article-title":"Approved and experimental small-molecule oncology kinase inhibitor drugs: a mid-2016 overview","volume":"37","author":"Fischer","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2018.11.014_bib0575","first-page":"23","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2018.11.014_bib0580","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/S0960-894X(01)00344-4","article-title":"Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer","volume":"11","author":"Barker","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2018.11.014_bib0585","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0590","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s40265-013-0111-6","article-title":"Afatinib: first global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2018.11.014_bib0595","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.3747\/co.25.3732","article-title":"Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer","volume":"25","author":"Abdallah","year":"2018","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0600","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1021\/jm500973a","article-title":"Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor","volume":"57","author":"Finlay","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2018.11.014_bib0605","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0610","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-018-0566-1","article-title":"Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and\/or leptomeningeal disease","volume":"13","author":"Hochmair","year":"2018","journal-title":"Target. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0615","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jsb.2015.10.018","article-title":"Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed","volume":"192","author":"Yosaatmadja","year":"2015","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0620","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0625","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1158\/0008-5472.CAN-07-1885","article-title":"PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib","volume":"67","author":"Engelman","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2018.11.014_bib0630","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-16-0281","article-title":"AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients","volume":"15","author":"Xu","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2018.11.014_bib0635","article-title":"Progress in adjuvant systemic therapy for breast cancer","author":"Pond\u00e9","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0640","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ctrv.2018.04.016","article-title":"Treatment of advanced HER2-positive breast cancer: 2018 and beyond","volume":"67","author":"Pond\u00e9","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2018.11.014_bib0645","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.amjsurg.2016.02.013","article-title":"Mutation spectra of RAS gene family in colorectal cancer","volume":"212","author":"Chang","year":"2016","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.phrs.2018.11.014_bib0650","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/atm.2018.03.27","article-title":"Colorectal cancer genomics and designing rational trials","volume":"6","author":"Mondaca","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.phrs.2018.11.014_bib0655","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1200\/JCO.2008.21.2134","article-title":"Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology","volume":"27","author":"Winer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0660","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2018.11.014_bib0665","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.phrs.2018.11.014_bib0670","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181831747X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181831747X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:00:20Z","timestamp":1760911220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181831747X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":134,"alternative-id":["S104366181831747X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.11.014","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}